Enterprise AI
AI drug discovery
Also known as: drug discovery, AI-driven drug discovery, computational drug discovery
AI drug discovery is the use of machine learning and computational models to support the early stages of finding and refining new medicines. Models are applied to tasks such as predicting protein structures, identifying candidate molecules, prioritising targets and estimating properties like toxicity or binding affinity. The aim is to narrow a very large search space before expensive laboratory and clinical work begins.
What it is
It covers a set of computational methods applied across target identification, hit discovery, lead optimisation and preclinical assessment. Approaches include structure prediction, generative chemistry, virtual screening of compound libraries and predictive models built on experimental and literature data. AI-derived predictions still require wet-lab validation and the usual regulatory process before anything reaches patients.
Why it matters
For marketers and communicators in life sciences, AI drug discovery is both a commercial category and a communications minefield, because claims about speed and success are closely scrutinised by investors, clinicians and regulators. Buyers in this space research through scientific literature, conferences and peer networks as much as through search. Accurate, well-sourced content is what earns citation in AI answers and credibility with technical audiences.
How it works
Organisations combine proprietary experimental data with public datasets, train or fine-tune models for specific prediction tasks, and feed ranked candidates into laboratory testing that in turn improves the models. Commercially, platform companies license software, run discovery partnerships with pharmaceutical firms, or advance their own pipelines. Content teams support this with technical explainers, published research, case detail and clear statements of what has and has not been validated.
When it applies
It applies to biotech and pharmaceutical organisations, contract research providers and software vendors working on early-stage discovery, and to any agency or in-house team marketing to those audiences.
Examples
- A platform company publishes a technical explainer on how its model ranks candidate molecules, aimed at medicinal chemists evaluating partnerships.
- A biotech uses virtual screening to reduce a large compound library to a shortlist for laboratory assay testing.
- A communications team reviews website copy to ensure pipeline stages are described accurately rather than implying approved treatments.
How it is measured
- Citations of your published research and technical content in scientific literature and AI answers
- Qualified partnership or licensing enquiries attributed to content and search
- Share of visibility for category terms such as target identification or generative chemistry
- Engagement from technical roles, measured by job title in enquiry and event registration data
Insights on AI drug discovery
Related terms in Enterprise AI
- AI agentsAI agents are software systems that use a language model to plan and carry out multi-step tasks, rather than simply returning a block of text. They can call tools, query APIs, browse websites and write to other systems in pursuit of a goal, with varying degrees of human oversight. The term covers everything from a scripted assistant that books a meeting to a research agent that gathers sources and drafts a report.
- AI chipsAI chips are processors designed or optimised to run machine learning workloads, especially the large matrix operations behind training and inference. The category covers GPUs, tensor and neural processing units, and custom ASICs, usually paired with high-bandwidth memory and fast interconnects. They are also called AI accelerators or AI semiconductors.
- AI infrastructureAI infrastructure is the stack of hardware, networking, storage and software needed to train, fine-tune and serve AI models at scale. It spans accelerators such as GPUs, the data centres and power that house them, and the orchestration and serving layers that turn raw compute into working model endpoints. For most marketing teams it is a cost and capacity constraint they consume through APIs rather than something they build.
- AI procurementAI procurement is the process of evaluating, buying and contracting artificial intelligence tools and services, from assistants and content platforms to models accessed through an application programming interface. It covers commercial terms alongside security, data protection, accuracy and integration questions that do not arise with ordinary software. Most organisations run it as a structured review with pilots, stakeholder sign off and defined exit conditions.
- AI securityAI security is the practice of protecting AI systems, their data and the applications built on them from misuse, manipulation and leakage. It covers threats such as prompt injection, data exfiltration through model outputs, unsafe tool use by agents and compromised supply chains. It also covers the controls that keep AI features safe once they are live.
- AI triageAI triage is the use of machine learning or language models to sort, prioritise and route incoming cases so that the most urgent or most suitable ones reach the right person first. It is used in clinical settings for symptom assessment and in service operations for tickets, leads and enquiries. The system classifies and ranks, while a human usually makes the final decision.
Primary research · August 2026
How ChatGPT Shortlists Software Brands
An audit across 10 categories and 60 buying questions. I recorded what ChatGPT reads, throws away and links to when a buyer asks it which software to buy, and what that decides.
- 60
- Questions asked
- 10
- Software markets
- 2,680
- Results read
- 367
- Links shown
Free download
Get the full report
35 pages · PDF · 536 KB. Enter your details and it downloads straight away.